Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
Posted on: Monday, 2 November 2009, 17:00 CST
OVERLAND PARK, Kan., Nov. 2 /PRNewswire/ -- Vince and Associates Clinical Research (VACR), a leading provider of Phase I-IV clinical research trials, announced that Dr. Bradley Vince, Medical Director and President, shared his expertise at the Exploratory Development World Congress on October 20, 2009 in Boston, Massachusetts. The Exploratory Development World Americas Congress focuses on early development strategy, including a wide range of disciplines within clinical trials including Clinical Research, Clinical Pharmacology, Phase I Trials, Exploratory Development, Regulatory Affairs, PK/PD and Clinical Operations.
The pre-conference workshop facilitated by Lorraine M. Rusch, PhD, Vice President of Business Development at VACR, was entitled Mitigating Risk in Early Clinical Development. During the session, Dr. Vince discussed Recruiting Strategies and Medical Oversight of Special Population Volunteers in Early Stage Trials. Dr. Vince related his physician perspective on the recruitment and medical management of intent-to-treat populations during early clinical research trials which enable earlier Proof of Concept (POC) drug development data to be successfully obtained.
"As a multi-specialty research unit, Vince and Associates Clinical Research is a leading provider of Phase I-IV clinical research for the pharmaceutical and biotechnology industry," said Dr. Vince. "We welcomed the opportunity to share our perspective, medical expertise and strength in early-stage drug development data at the Exploratory Development World Congress."
As the Medical Director of the Vince and Associates Clinical Research, Dr. Vince provides overall management of Phase I-IV clinical pharmacology services, including study design, feasibility, recruiting and monitoring of both healthy normal subjects and special population patients participating in clinical trials at the Overland Park, Kansas facilities.
Vince and Associates Clinical Research is a dedicated research facility that conducts Phase I-IV clinical trials for the global pharmaceutical and biotech industry. Dr. Vince has personally assembled an experienced team that focuses on quality research data and exceptional customer service while maintaining the highest ethical and professional standards. Vince and Associates has become one of the premier U.S. clinical research sites specializing in multispecialty trials. With over 275 clinical trials completed and having worked with over 70 sponsors and CROs, Vince and Associates is well known and respected for its rapid study start-up and quality study data.
Additional background materials pertaining to Vince and Associates Clinical Research is located on the corporate website at www.vinceandassociates.com.
Bruce Copeland 913-696-1601 bcopeland@vinceandassociates.comSOURCE Vince and Associates Clinical Research
Source: PR Newswire
Related Articles
- Dr. Eliseo Oreste Salinas to Join Adolor Corporation As Senior Vice President Research & Development and Chief Medical Officer
- Rexinoid Developed By NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- The Angeles Clinic and Research Institute Initiates Global Phase 3 Clinical Trial for New Melanoma Drug
- VNUS Medical Technologies Appoints Kirti Kamdar As Senior Vice President of Research & Development
- Synvista Therapeutics Appoints Carl M. Mendel, M.D. Vice President, Clinical Development and Chief Medical Officer
- Molecular Insight Pharmaceuticals, Inc. Announces Appointment of Norman LaFrance, M.D., As Senior Vice President, Clinical Development and Chief Medical Officer
- Genmab Hosts Research, Development and Business Update
- Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
- Microbia Appoints Dr. Jeffrey M. Johnston As Vice President, Clinical Development and Chief Medical Officer
 |
 |
User Comments (0)
RSS Feeds